These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2133113)

  • 1. C-MYC: evidence for multiple regulatory functions.
    Penn LJ; Laufer EM; Land H
    Semin Cancer Biol; 1990 Feb; 1(1):69-80. PubMed ID: 2133113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myc gene family proteins and their role in transformation and differentiation.
    Ingvarsson S
    Semin Cancer Biol; 1990 Dec; 1(6):359-69. PubMed ID: 2103508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
    Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
    Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of c-Myc and Max binding to the c-myc promoter: evidence that autosuppression occurs via an indirect mechanism.
    Buckle RS; Méchali M
    Oncogene; 1995 Mar; 10(6):1249-55. PubMed ID: 7700652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
    Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
    Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of the N-terminal domain of the Myc oncoprotein.
    Oster SK; Mao DY; Kennedy J; Penn LZ
    Oncogene; 2003 Apr; 22(13):1998-2010. PubMed ID: 12673205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions.
    Koskinen PJ; Ayer DE; Eisenman RN
    Cell Growth Differ; 1995 Jun; 6(6):623-9. PubMed ID: 7669717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translocations involving c-myc and c-myc function.
    Boxer LM; Dang CV
    Oncogene; 2001 Sep; 20(40):5595-610. PubMed ID: 11607812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene.
    Kuschak TI; Kuschak BC; Taylor CL; Wright JA; Wiener F; Mai S
    Oncogene; 2002 Jan; 21(6):909-20. PubMed ID: 11840336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
    Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
    J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation.
    La Rocca SA; Crouch DH; Gillespie DA
    Oncogene; 1994 Dec; 9(12):3499-508. PubMed ID: 7970710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Myc does not require max for transcriptional activity in PC-12 cells.
    Ribon V; Leff T; Saltiel AR
    Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
    Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of Nmi, a novel partner of Myc proteins.
    Bao J; Zervos AS
    Oncogene; 1996 May; 12(10):2171-6. PubMed ID: 8668343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
    Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
    Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition of the activities and properties of c-myc required to inhibit cell differentiation.
    Freytag SO; Dang CV; Lee WM
    Cell Growth Differ; 1990 Jul; 1(7):339-43. PubMed ID: 2278885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.